(-1.57%) 5 035.69 points
(-1.49%) 37 816 points
(-2.04%) 15 658 points
(-0.89%) $81.20
(-2.11%) $1.949
(-0.17%) $2 299.00
(0.00%) $26.66
(-0.38%) $944.60
(0.11%) $0.938
(0.26%) $11.12
(0.10%) $0.801
(0.00%) $93.45
-0.88% ¥ 1 013.00
Live Chart Being Loaded With Signals
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally...
Stats | |
---|---|
Dagens volum | 111 500 |
Gjennomsnittsvolum | 359 922 |
Markedsverdi | 121.98B |
EPS | ¥0 ( 2024-02-14 ) |
Neste inntjeningsdato | ( ¥14.90 ) 2024-05-09 |
Last Dividend | ¥42.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 77.98 |
ATR14 | ¥0.715 (0.07%) |
Volum Korrelasjon
Takara Bio Inc. Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Takara Bio Inc. Korrelasjon - Valuta/Råvare
Takara Bio Inc. Økonomi
Annual | 2022 |
Omsetning: | ¥78.14B |
Bruttogevinst: | ¥44.77B (57.29 %) |
EPS: | ¥132.97 |
FY | 2022 |
Omsetning: | ¥78.14B |
Bruttogevinst: | ¥44.77B (57.29 %) |
EPS: | ¥132.97 |
FY | 2022 |
Omsetning: | ¥67.70B |
Bruttogevinst: | ¥49.21B (72.69 %) |
EPS: | ¥164.84 |
FY | 2021 |
Omsetning: | ¥46.09B |
Bruttogevinst: | ¥31.87B (69.16 %) |
EPS: | ¥79.29 |
Financial Reports:
No articles found.
Takara Bio Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥42.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.000 | 2012-03-28 |
Last Dividend | ¥42.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 13 | -- |
Total Paid Out | ¥114.10 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.76 | -- |
Div. Sustainability Score | 8.16 | |
Div.Growth Potential Score | 6.07 | |
Div. Directional Score | 7.11 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6138.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
4845.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4047.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3276.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
2301.T | Ex Dividend Knight | 2023-10-30 | Semi-Annually | 0 | 0.00% | |
9232.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
8002.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7244.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
6474.T | Ex Dividend Junior | 2023-11-29 | Annually | 0 | 0.00% | |
5658.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0330 | 1.500 | 9.34 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0128 | 1.200 | 9.57 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0141 | 1.500 | -0.954 | -1.431 | [0.1 - 1] |
payoutRatioTTM | 3.21 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 7.45 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.46 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.25 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 61.42 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 200.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 81.73 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.553 | 1.000 | 4.11 | 4.11 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0309 | 1.000 | -1.382 | -1.382 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.387 | 0.800 | -0.751 | -0.601 | [0.5 - 2] |
Total Score | 8.16 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 78.26 | 1.000 | 2.20 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0141 | 2.50 | -0.613 | -1.431 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 81.73 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.665 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 200.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 3.21 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.725 | 1.500 | 8.50 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.506 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 6.07 |
Takara Bio Inc.
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.